27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
The US Food and Drug Administration (FDA) on Friday approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 28 September 2024
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
US pharma giant Pfizer and German partner BioNTech have reached agreement with the US government to provide an additional 500 million doses of their COVID-19 vaccine – trade-named Comirnaty - at a not-for-profit price for donation to low- and lower-middle-income countries and the organizations that support them 22 September 2021
Announcing a second Asian out-licensing deal for its rare liver disease drug candidate, US biotech Mirum Pharmaceuticals has now granted exclusive rights to market maralixibat in Japan to Takeda Pharmaceutical. 22 September 2021
A combination of Phase III data and real-world evidence show the safety and efficacy of offering a booster shot of Johnson & Johnson’s coronavirus vaccine. 22 September 2021
Canada’s AbCellera (Nasdaq: ABCL) today announced the European Commission (EC) and Eli Lilly (NYSE: LLY) have entered into a joint procurement agreement to supply up to 220,000 doses of bamlanivimab together with etesevimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. 22 September 2021
US biotech bluebird bio says it has completed the rolling submission of its Biologics License Application (BLA) to the US Food and Drug Administration for betibeglogene autotemcel (beti-cel) gene therapy in adult, adolescent and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions, across all genotypes. 22 September 2021
Research undertaken at the University of Bristol, UK, paves the way for a novel artificial intelligence (AI)-driven platform for growing and treating virtual tumors. 22 September 2021
Pharma giant Novartis today announced that it has acquired fellow Switzerland-based Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. 22 September 2021
The US Food and Drug Administration has approved Cabometyx (cabozantinib) for the additional indication of the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible. 21 September 2021
Privately-held US immune-oncology firm Vigeo Therapeutics today announced completion of the Phase I/II dose expansion studies evaluating its lead asset VT1021 in recurrent glioblastoma (rGBM) and pancreatic cancer. 21 September 2021
German family-owned drugmaker Boehringer Ingelheim says it has acquired Abexxa Biologics, a biopharmaceutical company taking a new approach in the fields of immuno-oncology (I-O) and oncology research to develop the next generation of precision medicines designed to revolutionize cancer treatments. 21 September 2021
US cancer specialist Verastem Oncology saw its shares briefly spike by as much as 29% Monday morning, after announcing a clinical collaboration agreement with biotech major Amgen to evaluate the combination of VS-6766, Verastem’s investigational dual RAF/MEK inhibitor, with Amgen’s KRAS G12C inhibitor Lumakras (sotorasib) in KRAS G12C-mutant non-small cell lung cancer (NSCLC). 21 September 2021
Research from industry analyst GlobalData finds an increasing rate of dealmaking in India in recent quarters, propelled by the coronavirus pandemic. 21 September 2021
Data from the Phase III IMpower010 trial testing Tecentriq (atezolizumab) after surgery and chemo in lung cancer show a 34% reduction in the risk of disease recurrence or death. 21 September 2021
Uwe Trinks, global practice lead for pharmacovigilance technologies, IQVIA, provides an Expert View on how the pharmaceutical industry can make a success of new working practices. 21 September 2021